文章：

推进生殖细胞肿瘤管理：miR-371a-3p及其他微小RNA与传统血清肿瘤标志物的比较综述

Advancing GCT Management: A Review of miR-371a-3p and Other miRNAs in Comparison to Traditional Serum Tumor Markers

原文发布日期：31 March 2024

DOI: 10.3390/cancers16071379

类型: Article

开放获取: 是

英文摘要：

MicroRNAs, short non-protein coding RNAs, are overexpressed in GCTs. Circulating levels of germ cell tumor (GCT)-associated miRNAs, such as miR-371a-3p, can be utilized as efficient and cost-effective alternatives in diagnosing and managing patients presenting with GCTs. This quality of miRNAs has demonstrated favorable performance characteristics as a reliable blood-based biomarker with high diagnostic accuracy compared to current serum tumor markers (STMs), including α-fetoprotein (AFP), beta human chorionic gonadotropin (β-hCG), and lactate dehydrogenase (LDH). The conventional STMs exhibit limited specificity and sensitivity. Potential clinical implications of miRNAs include impact on de-escalating or intensifying treatment, detecting recurrence at earlier stages, and lessening the necessity of cross-sectional imaging or invasive tissue biopsy for non-teratomatous GCTs. Here, we also highlight the outstanding issues that must be addressed prior to clinical implementation. Standards for measuring circulating miRNAs and determining ideal cutoff values are essential for integration into current clinical guidelines.

摘要翻译： 

微小核糖核酸（microRNAs）是一类短链非编码蛋白质的RNA分子，在生殖细胞肿瘤（GCTs）中呈现过表达状态。循环血液中与生殖细胞肿瘤相关的微小核糖核酸（如miR-371a-3p）可作为诊断和管理GCT患者的高效且经济的选择。相较于当前常用的血清肿瘤标志物（STMs），如甲胎蛋白（AFP）、人绒毛膜促性腺激素β亚基（β-hCG）和乳酸脱氢酶（LDH），微小核糖核酸展现出优越的性能特征，成为一种可靠的血源性生物标志物，具有较高的诊断准确性。传统的血清肿瘤标志物在特异性和敏感性方面存在局限。微小核糖核酸潜在的临床意义包括：影响治疗方案的降级或强化、在更早阶段检测肿瘤复发，以及减少非畸胎瘤性生殖细胞肿瘤患者进行横断面影像学检查或侵入性组织活检的必要性。本文同时强调了在临床推广应用前必须解决的关键问题，包括建立循环微小核糖核酸的检测标准及确定最佳截断值，这对于将其纳入现行临床指南至关重要。

原文链接：

Advancing GCT Management: A Review of miR-371a-3p and Other miRNAs in Comparison to Traditional Serum Tumor Markers